There’s no “I” in “Nutramax”
This article was originally published in The Tan Sheet
Executive Summary
Cosamin DS joint health supplement maker Nutramax is challenging a trademark application for Nutrimax in the U.S. for the same class of products registered under its brand name, the Edgewood, Md.-based company announces. The firm filed an opposition with the U.S. Patent and Trademark Office as well as a court complaint citing trademark infringement. The U.S. District Court for the District of Maryland July 17 granted the firm's motion for judgment by default effectively barring Los Angeles-based Nutrimax USA from advertising, promoting and/or offering to market any dietary supplement products containing the word "Nutrimax," and requires it to destroy all documents containing the word and modify all Web sites and electronic files...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.